Syngenis-backed venture Gene S Dx acquires Australian pharmacogenomics platform Rosa
What's the deal? Perth life sciences company Syngenis LabsDealroom has a profile for this one. Try Dealroom → has teamed with the Perron InstituteDealroom has a profile for this one. Try Dealroom → and the scientists behind Gene SDealroom has a profile for this one. Try Dealroom → to form Gene S Dx, a new precision-medicine venture that has acquired the Gene S business and its Rosa pharmacogenomics platform. Terms were not disclosed. Syngenis, via its Syngenis Ventures arm, will own one-third of Gene S Dx.
Who owns what? The Perron Institute and Gene S founders Dr Svetlana Baltic and Dr Suzanna Lindsey-Temple will collectively hold the remaining two-thirds. The deal transfers the Gene S business, the Rosa platform, and the underlying development intellectual property to Gene S Dx.
What is Rosa? Named after DNA pioneer Rosalind Franklin, Rosa pairs next-generation genetic sequencing with proprietary RosaAnalyser software. It turns a patient's genetic data into a clinician-ready report — usually within two to three days from a single blood, buccal, or saliva sample — showing how they may metabolise or respond to particular medicines and doses.
Why does it matter? Pharmacogenomics uses a patient's genetic make-up to help determine which medicines and doses may work best. For Syngenis, the deal advances its integrated biotechnology model, combining equity with its DNA and RNA expertise, laboratory infrastructure, and manufacturing capacity.
What's the endgame? Syngenis is building an Australian end-to-end genetic medicine platform spanning AI-assisted discovery, laboratory development, and GMP-regulated manufacturing. With Gene S in the fold, it can bring its nucleic-acid chemistry to Rosa and manufacture the oligonucleotide components of its test kits in Australia.
Its research-grade manufacturing operation at Bentley Technology Park in Perth already generates revenue, while clinical-grade GMP manufacturing is targeted for 2027.
Managing director Thomas Hanly stressed the acquisition is about capability, not a single product. "We have not bought a test," he said. What Syngenis gained, he added, is the science and the interpretation layer between a patient's genome and their doctor's prescription.
The signal: The deal reflects a push to keep more of the genetic-medicine value chain onshore. As Hanly put it, Syngenis can now design panels and produce kits at volume "here, rather than watching the supply chain run offshore."
Read more: thewest.com.au
Image credit: U.S. Department of Energy
